This site is intended for US
patients only.
This site is intended for US
healthcare professionals.
This site is intended for US
patients only.
This site is intended for US
healthcare professionals.
Learn about the ETON CARES® support program and download the patient information booklet on starting and staying on treatment with INCRELEX® (mecasermin). You can also find links to useful online resources to help you when you start your INCRELEX® treatment journey.
Please see Indication and Important Safety Information below.
Olive, a former INCRELEX patient, at age 18
A prescription for INCRELEX® (mecasermin) automatically enrolls you in the Eton Cares Program® . Through the program, eligible, commercially insured patients can receive their medication for a co-pay of $0.*
Your doctor sent prescription to our speciality pharmacy Anovo.
Please contact us at our speciality pharmacy Anovo® .
*Restrictions, limitations, and/or eligibility requirements apply.
The MAGIC (Major Aspects of Growth in Children) Foundation for children’s growth is an American nonprofit organization. The Foundation helps families of children diagnosed with growth-impacting medical conditions through education, networking, and many other services.
The Human Growth Foundation is an American nonprofit organization that is actively involved in patient advocacy, endocrine research, and provides family education and support on growth disorders and their treatment. The Foundation’s vision includes helping children with growth disorders and their healthcare providers by increasing awareness and the importance of early diagnosis and treatment.
INCRELEX® (mecasermin) is a prescription medicine used in children 2 years and older with short stature that have severely low levels of the hormone, insulin-like growth factor-1 (IGF-1). IGF-1 is needed for normal growth.
INCRELEX is not a substitute for growth hormone. It cannot be used for children with short stature due to low levels of growth hormone, malnutrition, when their thyroid gland doesn’t make enough thyroid hormone, or when taking anti-inflammatory steroids used to manage inflammation.
Always give INCRELEX exactly as your doctor directed.
Do not take INCRELEX if you are allergic to IGF-1 or any of its other ingredients. Report any allergic reactions.
INCRELEX should be injected under the skin (subcutaneous injection). It should not be injected directly into a blood vessel.
INCRELEX should not be used after growth plates close which happens during puberty.
INCRELEX should not be used in children with cancerous tumors or a history of cancer.
Hypoglycemia (low blood sugar): INCRELEX should be administered 20 minutes before or after a meal or snack and should not be administered when the meal or snack is skipped.
Intracranial Hypertension: Increased pressure in your skull may occur because of cerebrospinal fluid buildup around your brain. Therefore, your doctor may require an eye examination at the start of INCRELEX treatment and periodically during the time you are taking INCRELEX.
Lymphoid Tissue Hypertrophy: Lymphoid tissue hypertrophy is a noncancerous increase in the number of immune cells called lymphocytes. Patients should have periodic examinations with your doctor to rule out potential complications.
Slipped Capital Femoral Epiphysis: Slipped capital femoral epiphysis is a bone problem where the top of the upper leg (femur) slips apart. This may lead to a serious condition where bone tissue dies due to a lack of blood supply (osteonecrosis). Get medical help for your child right away if your child develops a limp or has hip or knee pain.
Progression of Scoliosis: Your doctor will monitor you during treatment with INCRELEX if you have a history of scoliosis.
Malignant Neoplasia: There have been reports of cancerous tumors in children who received INCRELEX. It is unknown whether there is any relationship between INCRELEX therapy and new occurrence of tumors. Tumors were mostly reported in patients with rare genetic conditions of short stature associated with a higher risk of cancer, or in patients already at risk of cancer.
Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preserved Solution: Serious and fatal adverse reactions can occur in neonates and infants treated with benzyl alcohol-preserved drugs. Use of INCRELEX in infants is not recommended.
The most common adverse reactions include low blood sugar, reactions at the injection site or throughout your body, and enlarged tonsils.
You are encouraged to report negative side effects of prescription drugs by contacting Eton Pharmaceuticals, Inc. at 1-855-224-0233 or the U.S. Food and Drug Administration (FDA) at www.fda.gov/safety/Medwatch or call 1-800-FDA-1088.
Please see full Prescribing Information for more information.
INCRELEX® (mecasermin) is a prescription medicine used in children 2 years and older with short stature that have severely low levels of the hormone, insulin-like growth factor-1 (IGF-1). IGF-1 is needed for normal growth.
INCRELEX is not a substitute for growth hormone. It cannot be used for children with short stature due to low levels of growth hormone, malnutrition, when their thyroid gland doesn’t make enough thyroid hormone, or when taking anti-inflammatory steroids used to manage inflammation.
Always give INCRELEX exactly as your doctor directed.
Do not take INCRELEX if you are allergic to IGF-1 or any of its other ingredients. Report any allergic reactions.
INCRELEX should be injected under the skin (subcutaneous injection). It should not be injected directly into a blood vessel.
INCRELEX should not be used after growth plates close which happens during puberty.
INCRELEX should not be used in children with cancerous tumors or a history of cancer.
Hypoglycemia (low blood sugar): INCRELEX should be administered 20 minutes before or after a meal or snack and should not be administered when the meal or snack is skipped.
Intracranial Hypertension: Increased pressure in your skull may occur because of cerebrospinal fluid buildup around your brain. Therefore, your doctor may require an eye examination at the start of INCRELEX treatment and periodically during the time you are taking INCRELEX.
Lymphoid Tissue Hypertrophy: Lymphoid tissue hypertrophy is a noncancerous increase in the number of immune cells called lymphocytes. Patients should have periodic examinations with your doctor to rule out potential complications.
Slipped Capital Femoral Epiphysis: Slipped capital femoral epiphysis is a bone problem where the top of the upper leg (femur) slips apart. This may lead to a serious condition where bone tissue dies due to a lack of blood supply (osteonecrosis). Get medical help for your child right away if your child develops a limp or has hip or knee pain.
Progression of Scoliosis: Your doctor will monitor you during treatment with INCRELEX if you have a history of scoliosis.
Malignant Neoplasia: There have been reports of cancerous tumors in children who received INCRELEX. It is unknown whether there is any relationship between INCRELEX therapy and new occurrence of tumors. Tumors were mostly reported in patients with rare genetic conditions of short stature associated with a higher risk of cancer, or in patients already at risk of cancer.
Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preserved Solution: Serious and fatal adverse reactions can occur in neonates and infants treated with benzyl alcohol-preserved drugs. Use of INCRELEX in infants is not recommended.
The most common adverse reactions include low blood sugar, reactions at the injection site or throughout your body, and enlarged tonsils.
You are encouraged to report negative side effects of prescription drugs by contacting Eton Pharmaceuticals, Inc. at 1-855-224-0233 or the U.S. Food and Drug Administration (FDA) at www.fda.gov/safety/Medwatch or call 1-800-FDA-1088.
Please see full Prescribing Information for more information.
